![]() |
市場調查報告書
商品編碼
1498656
全球炭疽疫苗市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測Global Anthrax Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
預計到2032年,全球炭疽疫苗市場需求將從2023年的167.3億美元達到近281.6億美元的市場規模,2024-2032年研究期間的複合年成長率為5.96%。
炭疽疫苗是一種生物製劑,可提供針對引起炭疽的炭疽桿菌的免疫力。它主要用於高暴露風險的個人,例如軍事人員、實驗室工作人員和處理動物產品的個人。該疫苗以免疫系統為目標,產生針對細菌保護性抗原的抗體,從而提供針對感染的防禦。它是生物防禦和職業健康計劃的重要組成部分。
生物恐怖主義和生物戰的持續威脅,加上炭疽自然爆發的可能性,凸顯了炭疽疫苗接種作為公共衛生防範措施的至關重要性。這提高了人們對炭疽作為潛在生物安全威脅的認知,促使政府機構和國防組織儲存炭疽疫苗並投資疫苗接種計劃,從而提振了市場需求。疫苗開發和製造技術的進步促進了下一代炭疽疫苗的開發,其安全性得到改善,功效增強,劑量方案減少,從而推動了市場的採用和擴張。此外,增加政府對生物防禦計劃和新出現的傳染病的資助和研究撥款,透過支持疫苗研究和開發工作來刺激市場成長。
此外,不斷擴大的全球旅行和貿易網路增加了炭疽傳播和傳播的風險,推動了高風險地區和高風險族群(例如軍事人員、急救人員和實驗室工作人員)對炭疽疫苗的需求。此外,製藥公司、政府機構和研究機構之間的策略夥伴關係和合作促進了疫苗生產的可擴展性、法規核准和全球分銷,從而促進了市場成長。然而,潛在的副作用和有限的意識可能會挑戰未來幾年的市場成長。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具也對全球炭疽疫苗市場的各個細分市場進行了包容性評估。炭疽疫苗產業的成長和趨勢為本研究提供了整體方法。
炭疽疫苗市場報告的這一部分提供了國家和區域層面細分市場的詳細資料,從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。
本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲炭疽疫苗市場當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。炭疽疫苗市場的主要參與者包括Altimmune Inc.、Agrovet、Bayer AG、Bavarian Nordic、Biogenesis Bago SA、Ceva Sante Animale、Colondo Serum Company、Emergent BioSolutions、Elusys Therapeutics Inc.、IndianImmunologicals Ltd.、Solutions、Elusys Therapeutics Inc.、IndianImmunologicals Ltd.、Intervac (PVT) Ltd、 JOVAC、Merck Co Inc.、Proton Biopharma Ltd。和其他發展。
如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
The global demand for Anthrax Vaccine Market is presumed to reach the market size of nearly USD 28.16 Billion by 2032 from USD 16.73 Billion in 2023 with a CAGR of 5.96% under the study period 2024-2032.
The anthrax vaccine is a biological preparation that provides immunity against Bacillus anthracis, which causes anthrax. It is primarily used for individuals at high risk of exposure, such as military personnel, laboratory workers, and individuals handling animal products. The vaccine targets the immune system to generate antibodies against the bacterium's protective antigen, thereby providing defense against infection. It is a crucial component in biodefense and occupational health programs.
The persistent threat of bioterrorism and biological warfare, coupled with the potential for natural outbreaks of anthrax, underscores the critical importance of anthrax vaccination as a public health preparedness measure. This heightened awareness of anthrax as a potential biosecurity threat drives government agencies and defense organizations to stockpile anthrax vaccines and invest in vaccination programs, bolstering market demand. Advancements in vaccine development and manufacturing technologies have led to the development of next-generation anthrax vaccines with improved safety profiles, enhanced efficacy, and reduced dosage regimens, driving market adoption and expansion. Additionally, increasing government funding and research grants for biodefense initiatives and emerging infectious diseases stimulate market growth by supporting vaccine research and development efforts.
Moreover, expanding global travel and trade networks increase the risk of anthrax transmission and dissemination, driving demand for anthrax vaccines in high-risk regions and among at-risk populations, such as military personnel, first responders, and laboratory workers. Furthermore, strategic partnerships and collaborations between pharmaceutical companies, government agencies, and research institutions facilitate vaccine production scalability, regulatory approvals, and global distribution, fostering market growth. However, potential side effects and limited awareness may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anthrax Vaccine. The growth and trends of Anthrax Vaccine industry provide a holistic approach to this study.
This section of the Anthrax Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Anthrax Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anthrax Vaccine market include Altimmune Inc., Agrovet, Bayer AG, Bavarian Nordic, Biogenesis Bago SA, Ceva Sante Animale, Colondo Serum Company, Emergent BioSolutions, Elusys Therapeutics Inc., Indian Immunologicals Ltd., Intervac (PVT) Ltd, JOVAC, Merck Co Inc., Proton Biopharma Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.